Verve Therapeutics Valuation
| VERV Stock | USD 6.23 0.07 1.11% |
At this time, the company appears to be undervalued. Verve Therapeutics has a current Real Value of $15.44 per share. The regular price of the company is $6.23. Our model measures the value of Verve Therapeutics from inspecting the company fundamentals such as Current Valuation of 64.72 M, shares owned by insiders of 5.28 %, and Return On Equity of -0.41 as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Verve Therapeutics' valuation include:
Price Book 1.0372 | Enterprise Value 64.7 M | Enterprise Value Ebitda (0.40) | Price Sales 21.8635 | Enterprise Value Revenue 2.4099 |
Undervalued
Today
Please note that Verve Therapeutics' price fluctuation is somewhat reliable at this time. Calculation of the real value of Verve Therapeutics is based on 3 months time horizon. Increasing Verve Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Verve stock is determined by what a typical buyer is willing to pay for full or partial control of Verve Therapeutics. Since Verve Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Verve Stock. However, Verve Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 6.23 | Real 15.44 | Target 44.22 | Hype 6.21 |
The intrinsic value of Verve Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Verve Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Verve Therapeutics helps investors to forecast how Verve stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Verve Therapeutics more accurately as focusing exclusively on Verve Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Verve Therapeutics' intrinsic value based on its ongoing forecasts of Verve Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Verve Therapeutics' closest peers.
Verve Therapeutics Cash |
|
Verve Valuation Trend
Analysing the historical paterns of Verve Therapeutics' enterprise value and its market capitalization is a good way to estimate and gauge the value of Verve Therapeutics over time and is usually enough for investors to make rational market timing decisions.
Verve Therapeutics Total Value Analysis
Verve Therapeutics is at this time projected to have valuation of 64.72 M with market capitalization of 533.38 M, debt of 74.91 M, and cash on hands of 293.56 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Verve Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
64.72 M | 533.38 M | 74.91 M | 293.56 M |
Verve Therapeutics Investor Information
About 98.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 1.04. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Verve Therapeutics recorded a loss per share of 2.46. The entity had not issued any dividends in recent years. Based on the key indicators related to Verve Therapeutics' liquidity, profitability, solvency, and operating efficiency, Verve Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in January.Verve Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Verve Therapeutics has an asset utilization ratio of 1.56 percent. This indicates that the Company is making $0.0156 for each dollar of assets. An increasing asset utilization means that Verve Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Verve Therapeutics Ownership Allocation
Verve Therapeutics shows a total of 84.66 Million outstanding shares. The majority of Verve Therapeutics outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Verve Therapeutics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Verve Therapeutics. Please pay attention to any change in the institutional holdings of Verve Therapeutics as this could imply that something significant has changed or is about to change at the company. Also note that roughly two million six hundred seventy-five thousand three hundred seventy-six invesors are currently shorting Verve Therapeutics expressing very little confidence in its future performance.Verve Therapeutics Profitability Analysis
The company reported the previous year's revenue of 11.76 M. Net Loss for the year was (200.07 M) with loss before overhead, payroll, taxes, and interest of (128.15 M).About Verve Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Verve Therapeutics. We calculate exposure to Verve Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Verve Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 6.3 M | 6.6 M | |
| Pretax Profit Margin | (16.99) | (17.84) | |
| Operating Profit Margin | (18.98) | (19.93) | |
| Net Loss | (17.02) | (17.87) | |
| Gross Profit Margin | 0.54 | 0.56 |
Verve Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Verve Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 64.2 M |
Verve Therapeutics Current Valuation Indicators
Verve Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Verve Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Verve Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Verve Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Verve Therapeutics' worth.Additional Tools for Verve Stock Analysis
When running Verve Therapeutics' price analysis, check to measure Verve Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verve Therapeutics is operating at the current time. Most of Verve Therapeutics' value examination focuses on studying past and present price action to predict the probability of Verve Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verve Therapeutics' price. Additionally, you may evaluate how the addition of Verve Therapeutics to your portfolios can decrease your overall portfolio volatility.